Deanna Yamamura, DO
Cardiovascular Disease · Harlingen, TXNPI 1851752273
Payments from drug & device makers
Across 152 payments — averaging $73.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Johnson & Johnson$1K
- Medtronic$995
- Abiomed$779
- Amgen$486
- Boston Scientific$466
- plus $3K from 23 others
What the payments were for
- Grants$1401%
- Travel & lodging$2,21520%
- Food & beverage$8,48876%
- Education$2933%
- Entertainment$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 36 | $3,834 |
| Johnson & Johnson | 15 | $1,177 |
| Medtronic(2 entities) | 24 | $995 |
| Abiomed | 9 | $779 |
| Amgen | 6 | $486 |
| Boston Scientific | 12 | $466 |
| Actelion Pharmaceuticals US, Inc. | 5 | $444 |
| Cook Medical LLC | 3 | $437 |
| AstraZeneca | 4 | $284 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $232 |
| Amarin Pharma, Inc. | 2 | $199 |
| Chiesi USA, Inc. | 2 | $186 |
| Bard Peripheral Vascular, Inc. | 1 | $177 |
| Novartis | 4 | $165 |
| CSL Behring | 2 | $163 |
| EKOS Corporation | 3 | $147 |
| E.r. Squibb & Sons, L.L.C. | 1 | $124 |
| Cardiovascular Systems Inc. | 6 | $118 |
| Genentech USA, Inc. | 1 | $118 |
| Novo Nordisk | 1 | $115 |
| Pfizer | 1 | $99 |
| Portola Pharmaceuticals, LLC | 1 | $97 |
| Opsens Inc. | 2 | $91 |
| Regeneron | 1 | $80 |
| Philips North America LLC | 1 | $53 |
| Silk Road Medical, Inc. | 1 | $28 |
| Shockwave Medical, Inc | 1 | $21 |
| Penumbra, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNILINK ELITE$2,040
- XARELTO$611
- Cook Medical Peripheral Intervention$421
- CoreValve Evolut$385
- Repatha$348
- Impella$271
- FARXIGA$250
- PERCLOSE PROGLIDE$228
- OPSUMIT$220
- HeartMate 3 Left Ventricular Assist Device$212
- Supera peripheral stent system$161
- COREVALVE EVOLUT R$152
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$147
- HawkOne$131
- ENSITE$127
- ELIQUIS$124
- UPTRAVI$119
- Wegovy$115
- EKOSONIC$115
- CLEVIPREX$111
How this compares
$11,151 in reported general payments places this provider in the 70th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 113 | $141,775 |
| EntrestoSacubitril/Valsartan | 93 | $113,696 |
| EliquisApixaban | 83 | $90,777 |
| FarxigaDapagliflozin Propanediol | 47 | $51,537 |
| BrilintaTicagrelor | 22 | $11,475 |
| Metoprolol Succinate | 287 | $3,454 |
| Atorvastatin Calcium | 241 | $2,189 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 79 | $1,439 |
| ClopidogrelClopidogrel Bisulfate | 96 | $1,162 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 107 | $1,115 |
| Amlodipine Besylate | 172 | $937 |
| Ranolazine ErRanolazine | 17 | $817 |
| Losartan Potassium | 91 | $724 |
| Ezetimibe | 55 | $707 |
| Prazosin Hcl | 25 | $691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $1,177 | $141,775113 claims |
| NovartisEntresto | $165 | $113,69693 claims |
| PfizerEliquis | $99 | $90,77783 claims |
| AstraZenecaFarxiga, Brilinta | $284 | $63,01269 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Harlingen
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.